Table 6. Longitudinal analysis of IGH biclonal and multiclonal diversity in M-CLL, as determined by SCA.
| Absolute count, x109 cells/L (Clonal frequency) | ||||||
|---|---|---|---|---|---|---|
| Patient ID | Years after diagnosis | TLC, x109 cells/L | Clone 1 | Clone2 | Clone 3 | Clone 4 |
| CLL-43 a | 15 | 84 | 75.6 (90%) | 1.3 (1.6%) | NA | NA |
| 16 | 96 | 76.8 (80%) | 2.1 (2.2%) | NA | NA | |
| 19 | 131 | 114.0 (87%) | 5.8 (4.4%) | NA | NA | |
| 20 | 120 | 118.0 (98%) | 0.24 (0.2%) | NA | NA | |
| 22 | 92 | 83.7 (91%) | 4.1 (4.5%) | NA | NA | |
| CLL-105 b | 2 | 12.9 | 7.0 (54%) | 2.5 (19.5%) | 0.8 (6.5%) | 0.01 (0.1%) |
| 4 | 37 | 22.2 (60%) | 6.1 (16.4%) | 1.3 (3.6%) | 0.3 (0.9%) | |
| CLL-112 c | 0 | 26 | 20.1 (81%) | 1.5 (5.7%) | 1.4 (6%) | 2.0 (8%) |
| 1 | 36.3 | 25 (69%) | 6.9 (19%) | 0.7 (2%) | 1.1 (3%) | |
| 3 | 51 | 33.1 (65%) | 3.2 (6.2%) | 2.1 (4.2%) | 4.2 (8.3%) | |
| 5 | 37 | 36.6 (99%) | 0.15 (0.4%) | ND | ND | |
| CLL-129 d | 1 | 10.4 | 9.8 (94%) | 0.34 (3.3%) | NA | NA |
| 2 | 35 | 31.2 (89%) | 0.56 (1.6%) | NA | NA | |
| 2.5 | 45 | 43.2 (96%) | 1.9 (4.2%) | NA | NA | |
| 4 | 112 | 96.3 (86%) | 2.6 (2.3%) | NA | NA | |
| CLL-200 e | 4 | 11.1 | 8.0 (72%) | 0.47 (4.2%) | NA | NA |
| 7 | 11 | 7.8 (71%) | 0.24 (2.2%) | NA | NA | |
a clone 1, 43P_42/NP_64; clone 2, 43P_63
b clone 1, 105P_24; clone 2, 105P42A/NP_82; clone 3, 105P_45; clone 4, 105P_42
c clone 1, 112P_30; clone 2, 112P_45; clone 3, 112P_27; clone 4, 112P_51
d clone 1, 129P_47/NP_70; clone 2, 129P_45
e clone 1, 200P_60; clone 2, 200P_30
NA, not applicable; ND, detectable in bulk sample but not frequent enough to be detected in single cells or 12x100-cell aliquots; underlined, second clone with absolute count >5x109 cells/L.